News
Cimeio Therapeutics Therapy Platform Featured in Forbes Article
Cimeio Therapeutics innovative shielded-cell and immunotherapy pairs therapy platform was featured in a recent Forbes article discussing the industry push toward a universal blood cancer therapy.
Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers
Cimeio Therapeutics today announced a publication in Nature with findings that point to a novel and potentially universal approach to treating blood cancers.
Cimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT
Cimeio will be presenting data for its CD52 program during this week’s ASGCT meeting in Baltimore showing that T cells expressing an engineered CD52 can be effectively shielded from Alemtuzumab-mediated depletion.
Cimeio Therapeutics Presents Data for its CD45 Universal Heme ADC at ASH
Cimeio will be presenting posters at ASH 2023 that show CD45 ADC effectively eliminates AML cells in vivo, while CD45 epitope-edited healthy cells were shielded from ADC depletion.
Cimeio Therapeutics Announces Poster Presentations at ASH 2023
Cimeio will be presenting posters at ASH 2023 that show CD45 ADC effectively eliminates AML cells in vivo, while CD45 epitope-edited healthy cells were shielded from ADC depletion.
Cimeio Therapeutics Announces Research Collaboration With the University of Pennsylvania
Collaboration with the Center for Cellular Immunotherapies in the Perelman School of Medicine to conduct preclinical studies of a CD45 CAR T Cell Therapy.
Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine
Cimeio announces the publication of research showing that epitope edited human hematopoietic stem cells (HSCs) can be protected from targeted immunotherapies.
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome
Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform with the aim to reduce toxicity of conditioning regimens and introduce new therapeutic options that can expand the utility of hematopoietic stem cell (HSC) transplant and in vivo genetic therapies.
Cimeio Therapeutics Presents Additional Proof-of-Concept Data for SCIP Platform
Poster session at ASGCT meeting describes key progress with shielded CD45 cells.